Azithromycin Therapy Does Not Reduce Recurrent Wheeze After RSV
MONDAY, March 14, 2022 -- Azithromycin therapy during acute severe respiratory syncytial virus (RSV) bronchiolitis does not reduce recurrent wheeze over two to four years, according to a study published online Feb. 27 in NEJM Evidence. Avraham... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2022 Category: Pharmaceuticals Source Type: news

Azithromycin Doesn't Prevent Wheezing After Acute Infant RSV Azithromycin Doesn't Prevent Wheezing After Acute Infant RSV
Azithromycin administered for severe early-life respiratory syncytial virus bronchiolitis did not prevent recurrent wheezing in affected children over the next 2-4 years.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2022 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Infant Bronchiolitis Subtype May Predict Asthma Risk Infant Bronchiolitis Subtype May Predict Asthma Risk
Researchers identified four bronchiolitis subtypes that may determine infants at risk of asthma later in childhood.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 4, 2022 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

Ethnic Disparities Seen in Enrollment for a Clinical Trial ​
WEDNESDSAY, Jan. 19, 2022 -- In the Bronchiolitis Follow-up Intervention Trial (BeneFIT) setting, physicians more often determined that Hispanic patients were not appropriate for as-needed follow-up and excluded them from the trial, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2022 Category: Pharmaceuticals Source Type: news

Ask the Mayo Mom: RSV and bronchiolitis - what to expect this season
Respiratory syncytial virus (RSV) causes infections of the lungs and respiratory tract. It's so common that most children have been infected with the virus by age 2. RSV can cause severe infection in some people, especially premature infants, older adults, people with heart and lung disease, or anyone with a weak immune system. In severe cases, RSV infection can spread to the lower respiratory tract, causing pneumonia or bronchiolitis — inflammation of the small airway passages entering… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 17, 2021 Category: Databases & Libraries Source Type: news

Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults
RARITAN, N.J., October 2, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study results were presented as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2.“The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the severe ...
Source: Johnson and Johnson - October 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
RARITAN, N.J., September 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.The EVERGREEN study was initiated based on positive results from the Phase 2b CYPR...
Source: Johnson and Johnson - September 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bronchiolitis in children: diagnosis and management NICE guideline [NG9], (updated 9th August 2021)
This guideline covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. It describes treatments and interventions that can be used to help with the symptoms of bronchiolitis. In August 2021, the recommendations on oxygen saturation thresholds for referral to hospital, admission, management and timing of discharge were updated. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 13, 2021 Category: Consumer Health News Source Type: news

Data for Roche ’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atr ophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for at least five seconds* by month 12, a milestone not seen in the natural course of the disease. Safety for Evrysdi in the FIREFISH Part 2 study was consistent with its known safety profile.“Without treatme...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

Data for Roche ’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atr ophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for at least five seconds* by month 12, a milestone not seen in the natural course of the disease. Safety for Evrysdi in the FIREFISH Part 2 study was consistent with its known safety profile.“Without treatme...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news

National guidance for the management of children with bronchiolitis and lower respiratory tract infections during COVID-19, RCPCH (updated 19th July 2021)
These recommendations on the management of children with bronchiolitis and lower respiratory tract infections in hospital settings during COVID-19 are for clinicians to support winter planning in partnership with local infection control prevention teams.Table 2: Temporal changes in prevalence of COVID-19 during the pandemic Updated 14 July 2021 The table shows how prevalence has changed between the initial peak, 23 March 2020, and now. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2021 Category: Consumer Health News Source Type: news

Use of Bronchodilators Down for Bronchiolitis Treatment in Infants
TUESDAY, July 6, 2021 -- Bronchodilator therapy for the treatment of bronchiolitis in infants decreased significantly from 2010 to 2018 , according to a study published online July 6 in Pediatrics. Kristen H. Shanahan, M.D., from Boston Children ' s... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 6, 2021 Category: Pharmaceuticals Source Type: news

National guidance for the management of children with bronchiolitis and lower respiratory tract infections during COVID-19, RCPCH (updated 28th June 2021)
These recommendations on the management of children with bronchiolitis and lower respiratory tract infections in hospital settings during COVID-19 are for clinicians to support winter planning in partnership with local infection control prevention teams.Temporal changes in prevalence of COVID-19 during the pandemic Updated 28 June 2021 The table below shows how prevalence has changed between the initial peak, 23 March 2020, and now. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 2, 2021 Category: Consumer Health News Source Type: news

Distinct Molecular Subtypes of RSV Bronchiolitis Identified
Four biologically and clinically meaningful endotypes identified; asthma risk higher for endotype B compared with endotype A (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 21, 2021 Category: Respiratory Medicine Tags: Family Medicine, Infections, Pathology, Pediatrics, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news

Distinct Molecular Subtypes of RSV Bronchiolitis Identified
MONDAY, June 21, 2021 -- Distinct molecular subtypes of respiratory syncytial virus (RSV) bronchiolitis have been identified and are associated with differing levels of asthma risk, according to a study published online June 14 in Nature... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2021 Category: Pharmaceuticals Source Type: news